ATS Corporation reported first-quarter fiscal 2027 results on August 6, 2026, with adjusted revenues declining 5.2% year over year to $698 million. The drop reflects a lower opening order backlog and the planned reduction in large-scale automotive work.

Adjusted earnings from operations stood at $68.1 million, a 13.4% decrease compared to the same period last year. The company announced a new 18-month fixed cost transformation program aimed at achieving its long-term operating margin target of 15%.

Financial Performance Overview

The quarter’s performance highlights the impact of revenue mix shifts and execution timing. While top-line figures contracted, gross margin showed resilience due to higher-margin aftermarket services.

Order bookings totaled $656 million, down 5.3% from the prior-year period, which included large nuclear project awards. The company ended the quarter with an order backlog of approximately $1.9 billion, with Life Sciences, Food and Beverage, and Energy representing more than 80% of the total. SG&A expenses, excluding adjusting items, totaled $136.6 million, slightly higher than last year largely due to foreign exchange translation.

Fixed Cost Transformation Program

ATS initiated an 18-month program to simplify operations and reduce fixed costs. The initial phase focuses on Europe, targeting excess capacity and operating infrastructure. This phase is estimated to generate annualized savings of $20 million, representing approximately 30% of the total savings opportunities anticipated from the overall program.

Management indicated that about half of the margin improvement required to reach the 15% operating margin target will come from this fixed cost transformation. The remainder is expected to derive from growth in higher-margin aftermarket services and improved commercial discipline. CEO Doug Wright noted that the full quantum of savings could reach $70 million or more over time, though he emphasized a balanced approach to protect investments in high-growth markets like radiopharmaceuticals and nuclear energy. CFO Anne Cebulsky clarified that last year’s operating margin was approximately 10.6%, implying a need for roughly 500 basis points of expansion, with the cost program contributing about 250 basis points.

Balance Sheet and Capital Allocation

The company reported net debt to adjusted EBITDA of 2.9 times at the end of Q1, within its targeted range of two to three times for fiscal 27. Cash flows used in operating activities were $10 million, attributed to timing of billing and collections on larger programs. Non-cash working capital stood at 14.3% of revenues, remaining below the long-term target of 15%.

Capital expenditures and intangible asset investments totaled $15.6 million in the quarter. For fiscal 27, ATS expects total CapEx and intangible investment between $70 million and $90 million. The acquisition funnel remains active, with management maintaining flexibility to pursue strategic deals while adhering to disciplined return criteria. Doug Wright stated that while divisions undergoing significant cost reduction may have diminished capacity for M&A, the broader appetite for acquisitions remains unchanged, supported by a strengthened balance sheet.

Sector Dynamics and Outlook

In Life Sciences, the trailing twelve-month book-to-bill ratio excluding GLP-1 related activity was approximately 1.1 times, driven by strength in radiopharmaceuticals. Service-related revenues grew 11% year over year across the company. Conversely, bookings in nuclear were relatively weak due to timing, though management maintained confidence in long-term demand. Radiopharma backlog is now twice as material as GLP-1 backlog, positioning it as a key growth driver. Wright highlighted that individual isotope facilities represent a triple-digit addressable market opportunity for ATS.

For the second quarter of fiscal 2027, ATS expects revenues to range between $660 million and $700 million. The company anticipates margins to strengthen through the second half of the fiscal year as backlog converts and cost actions take effect. Management noted that while order slippage occurred in Q1, modest organic revenue growth remains achievable for the full year depending on the timing of larger customer awards. Wright added that the nature of long-cycle markets like nuclear and radiopharma creates inherent lumpiness in order rates, requiring patience regarding backlog velocity.

What the Numbers Show

A divergence exists between the decline in operational earnings and the stability of gross margins. While adjusted earnings from operations fell 13.4%, gross margin expanded by 18 basis points to 30%. This suggests that the profit compression was driven primarily by lower revenue volume and SG&A pressures rather than deteriorating unit economics or pricing power. Additionally, restructuring costs of $5.7 million were incurred against a guided spend of $10 million to $15 million, indicating that some workforce actions may have been deferred to subsequent quarters. The company also recorded $21.5 million in non-cash charges related to asset write-downs, which were adjusted out of non-GAAP metrics.

Levi & Korsinsky, LLP has initiated an investigation into ATS Corporation (NYSE: ATS) concerning potential violations of federal securities laws. The legal review was launched on Aug. 10, 2026, after ATS shares fell approximately 26.55% in the wake of the company’s first quarter fiscal 2027 earnings report released on Aug. 6, 2026. The investigation focuses on whether ATS adequately disclosed the condition and scope of its financial reporting controls, operating risks, and internal-control deficiencies to investors before the market absorbed the negative impact. This development poses significant legal and financial stakes for shareholders who purchased ATS securities during the alleged misrepresentation period and subsequently suffered losses.

The core of the investigation centers on ATS’s disclosure practices regarding demand pressures, backlog conversion rates, and fixed-cost burdens. Specifically, the firm is examining whether investors were properly informed about the need for a new 18-month fixed-cost transformation program, particularly given that ongoing restructuring efforts had already taken longer to implement than previously anticipated. The inquiry also scrutinizes whether the company adequately communicated the risks associated with these operational challenges prior to the sharp decline in stock value.

Q1 Fiscal 2027 Performance Drivers

The catalyst for the investigation was ATS’s disappointing first quarter fiscal 2027 results, which revealed year-over-year declines across key metrics. Revenue for the quarter totaled C$693.7 million, falling short of the company’s guided range of C$700 million to C$740 million by roughly C$6.3 million below the low end. This figure also came in below the C$724.0 million FactSet consensus estimate. Order bookings contracted by 5.3%, while adjusted earnings margin narrowed by 47 basis points. The company reported a net loss of C$0.3 million, a significant deviation from the net income of C$24.3 million recorded in the prior-year period.

On the August 6, 2026 earnings call, Interim CFO, VP, and Corporate Controller Anne Cybulski indicated the results "reflect[ed] the lower opening order backlog and the planned reduction in transportation-related activity." Notably, ATS’ reported backlog of C$1.889 billion had faltered 8.7% year-over-year and more than 3.5% sequentially. Levi & Korsinsky is investigating whether ATS may not have adequately disclosed the scale of these risks to investors.

ATS management attributed the setbacks to a combination of factors, including the timing of project execution, a more normalized level of GLP-1-related activities compared to the prior-year period, and the impacts of restructuring activities within its transportation businesses. The company noted that ongoing reorganization and restructuring activities had taken longer to implement than previously anticipated, prompting the announcement of the new 18-month fixed-cost transformation program.

What the Numbers Show

The divergence between ATS’s revenue performance and its margin compression highlights underlying structural pressures. While revenue declined by a moderate 5.8%, the simultaneous contraction in order bookings (5.3%) and the swing to a net loss suggest that cost management issues are outpacing top-line declines. The narrowing of adjusted earnings margin by 47 basis points indicates that fixed costs are not scaling down proportionally with reduced activity. This dynamic underscores the rationale behind the new 18-month transformation program, as the company attempts to align its cost base with normalized GLP-1-related activity levels and slower project execution timelines. The sequential drop in backlog further signals potential headwinds for future revenue realization.

Shareholder Eligibility and Next Steps

Shareholders who purchased ATS stock or securities and suffered financial losses may be eligible to participate in the investigation. Eligibility is determined by purchase date and documented losses, regardless of whether the investor still holds the shares. Those who sold ATS shares at a loss may still qualify. Participants are not required to appear in court or provide testimony, and there is no upfront cost to join the investigation, as it is handled on a contingency basis.

Interested parties are encouraged to gather brokerage records, including purchase dates, share quantities, and prices paid. They can submit their loss information or contact Joseph E. Levi, Esq., at Levi & Korsinsky, LLP via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500 for a free, no-obligation evaluation.